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Genetic engineering started as a science in 1861 when a monk Gregor 
Mendel discovered a concept which 120 years after his death would have 
revolutionised biology. 
His basic concept was this: the external characteristics of all organisms 
are governed by relatively simple laws which may be directly related to 
the existence of chemical factors in the organism itself. 
Discoveries slowly followed which led to the great discoveries of the 
1970s after which genetic engineering exploded into different branches of 
nearly all the biological sciences. 
Nowadays genetic engineering or molecular biology as it has also been 
called has a bearing which is considerable in the fields of drug 
production. 
One of the important steps which lead to genetic engineering as we know 
it today was the discovery of the restriction endonucleases which are 
enzymes having the property of restricting DNA at specified sites 
determined by the sequence of the amino acids. This together with the 
discovery and employment of the ligase and polymerase enzymes lead to 
the first proper genetic engineering experiment three years later which 
involved the insertion of a DNA molecule into a bacterium in such a way 
that the recombinant (as it is called) molecule is passed on to the 
offspring of the bacterium. Other discoveries followed and served to 
increase the utility and importance of the new science. Microorganisms 
were employed as vectors (holders for foreign DNA). This led to an array 
of tools including endonucleases, ligases, polymerase vectors, plasmids 
etc. with which the first drugs could be produced. Oncogenes were 
discovered in 1979. These oncogenes are genes which normally determine 
the rate and amount of growth in a mammalian cells and they have been 
discovered to be greatly implicated in cancerous growths. This discovery 
opened the path for genetic engineering to find a cure for at least some 
cancers. 
Today, a large amount of research is being conducted in the field so as to 
increase our understanding of the genome primarily of Homo sapiens and 
secondarily of other species. Bacteria are being utilised to house a 
predetermined section of genetic code. For example, if one needs to 
synthesize a determined protein of pharmacological interest which is not 
synthesized easily in vivo from the organism in which it is found 
naturally, the genetic code determining the structure of that protein is 
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isolated and inserted into a plasmid (a piece of circular DNA which has 
determined properties interesting to the scientist which assist in the 
future expression of the selected gene). This plasmid is inserted into a 
vector which at first normally consisted of a bacterium (Escherichia 
coli). Nowadays however genetic engineering of plants has advanced 
greatly and plants are being used both as vectors and as the source of the 
genetic code. In fact this could lead to great gains in pharmacological 
production since plants have always been a major source of drugs. Genetic 
engineering has the potential to greatly increase the output of drugs from 
plants as well as giving scientists the possibility of modifying micro 
organisms of modifying basic compounds to render them with greater 
activity and/or fewer side effects. 
Genetic engineering is therefore nowadays used to a great extent in drug 
production. There are various ways in which this technique may be used 
to manufacture drugs giving rise to a large (and ever increasing) amount 
of drugs and related compounds used in medicine. Some of the drugs and 
medicinal compounds produced by the industry can be seen below: 
Table 1 
Compound Initial Date Trade Name Use of the Drug 
Name Develop- Released 
Human 
Insulin 1977 1982 Humulin Diabetes 
Human 
Growth 
Hormone 1979 1985 Protropin Growth disorders 
Hepatitis B 
vaccine 1981 1986 Recombivax HB Hepatitis B 
IFN-
alpha 1977 1986 Roferon-A Various 
t-PA Tissue Plasminogen Myocardial 
(Activase) 1982 1987 Activator Infarction 
468 
Table 1 cont. 
ComfOund Initial Date Trade Name Use of the Drug 
Name Develop- Released 
EPO 
(erythro-
poietin 1984 1988 Epogen Anaemia 
IL-2 1982 1989 Proleukin AIDS, Cancer, 
Interleukin renal cell carcinoma 
-2 viral infections, 
rheumatoid arth-
rytis, lymphokine 
activated killer 
cell therapy 
IFN- 1979 1989 Immuneron renalcell carcinoma 
gamma Kaposi's sarcoma 
AIDS, skin cancer, 
rheumatoid arth-
ritis, bacterial 
infections 
Antihemo- 1983 1991 Factor VIII haemophilia 
philic factor 
G-CSF 1983 1991 Neupogen Chronic neutrope-
Granulocyte nia, cancer, bums, 
colony sti- leukemia, AIDS, 
mulating septicemia, bone 
factor marrow transplant 
actions in combi-
nation with chemo-
therapy 
(C) Editiones Roche, Basel, Switzerland 
The rate of drugs produced by different companies all over the world 
produced either directly by using genetic engineering or with the help of 
biotechnological techniques is always increasing. Some of the latest 
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products include a new revolutionary test for the HIV virus which 
sensitive and can detect infection with the virus after only 24 hours as 
compared with previous tests which could detect infection only after a 
period measured in months. 
Table 2: Impact of Genetic Engineering on Medicine 
Phase Impact on 
Pilot Phase Moderate 
1980-1985 Long term 
Biotech Increasing 
Phase as of Influence 
1984 
Pharmaco-
logical 
phase as of 
1990 
Major Pro-
gress in all 
areas 
Gene The- Innovative 
rapy phase Therapies 
as of 1995 
Substance 
Human Insulin 
Monoclonal 
Antibodies 
Interferons 
Applications 
Diabetes, Improved 
Diagnostics 
Viral infections 
Interleukins CSF Blood cancers and some 
tumours 
Viral components Some tumours. Immunode-
CD4 ficiency. Adjuncts to cancer 
therapy. New vaccines 
AIDS 
Agnosists and an- Cancer autoimmune 
tagonists of pro- diseases, immunodeficien-
teins genetically cy organ transplants CNS 
modified pro- diseases 
teins and anti-
bodies 
Genetic Diagnosis Diagnosis of inherited 
Somatic Cell gene diseases. Innovative 
therapy. Pharma- disease prevention. Some 
cological effect on Tumours, cure for inhe-
genetic activity rited disease 
(C) Editiones Roche, Basel, Switzerland 
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The table above gives a concise summary of the progress (actual and 
planned) of the science of genetic engineering when applied to drug 
production. 
As can be seen from the table new and important advances are planned 
and expected for genetic engineering . In the future one can expect to 
perform a genetic diagnosis and to cure inherited diseases of genetic 
origin directly by gene therapy. This type of cure has already been 
performed on a young patient with ADA. ADA is a rare genetic 
deficiency in which patients have an enzyme missing the enzyme 
adenosine deaminase which prevents the development of an immune 
system. Thus patients suffering from this disease have to live in a plastic 
bubble. Scientists are removing defective cells from a patient and 
inserted into an intact ADA gene into these cells and then reinfused these. 
cells into the patient. One hopes that these cells, which are now 
healthy, will multiply and replace the defective ones. The complete 
results of this experiments are still not known, however expectations are 
very optimistic. 
Other studies were carried out. The use of genetically engineered drugs in 
Malta were investigated as was the possibility of producing some drugs 
biotechnologically in Malta. Foreign companies were also asked to 
submit information as to what was the extent of their use of genetic 
engineering in their manufacturing processes. At the time of writing 
results for these experiments were not available. However the centres of 
biotechnology research and development seem to be centred in 
Switzerland and the United States. 
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